Pricing Agreement
Exhibit 1.2
August 1, 2022
Barclays Capital Inc.
As representative of the several Underwriters
named in Schedule I (the “Representative”)
Ladies and Gentlemen:
Barclays PLC (the “Company”) proposes to issue $2,000,000,000 aggregate principal amount of 8.000% Fixed Rate Resetting Perpetual Subordinated Contingent Convertible Securities (the “Designated Securities”). The Designated Securities are convertible in accordance with their terms for stock of Barclays PLC as described in the Preliminary Prospectus Supplement (as defined in Schedule II hereto). Each of the Underwriters hereby undertakes to purchase at the subscription price set forth in Schedule II hereto, the amount of Designated Securities set forth opposite the name of such Underwriter in Schedule I hereto, such payment to be made at the Time of Delivery set forth in Schedule II hereto. The obligations of the Underwriters hereunder are several but not joint.
Each of the provisions of the Underwriting Agreement—Standard Provisions, dated March 3, 2021 (the “Underwriting Agreement”), is incorporated herein by reference in its entirety, and shall be deemed to be a part of this Agreement to the same extent as if such provisions had been set forth in full herein; provided that, for the purposes of this letter, new Section 2(r) shall be included as follows: “The Company will promptly make a valid election in respect of the Designated Securities in accordance with the provisions of Section 475C of the Corporation Tax Xxx 0000 (“CTA 2009”). Following the making of a valid election pursuant to Section 475C of the CTA 2009, all payments of interest in respect of the Designated Securities will be deductible by the Company in computing its taxable profit for United Kingdom corporate income tax purposes and the Designated Securities will be “hybrid capital instruments” for United Kingdom tax purposes. The Designated Securities are not being issued in consequence of, or otherwise in connection with, any arrangements the main purpose, or one of the main purposes, of which is to secure a tax advantage;” and each of the representations and warranties set forth therein shall be deemed to have been made at and as of the date of this Agreement, except that each representation and warranty with respect to the Prospectus in Section 2 of the Underwriting Agreement shall be deemed to be a representation and warranty as of the date of the Prospectus and also a representation and warranty as of the date of this Agreement in relation to the Prospectus as amended or supplemented relating to the Designated Securities.
Each reference to the Representatives herein and in the provisions of the Underwriting Agreement so incorporated by reference shall be deemed to refer to you. Unless otherwise defined herein, terms defined in the Underwriting Agreement are used herein as therein defined. The Representative designated to act on behalf of each of the Underwriters of Designated Securities pursuant to Section 14 of the Underwriting Agreement and the address referred to in such Section 14 is set forth in Schedule II hereto.
An amendment to the Registration Statement, or a supplement to the Prospectus, as the case may be, relating to the Designated Securities, in the form heretofore delivered to you, is now proposed to be filed with the Commission.
The Applicable Time for purposes of this Pricing Agreement is 5.15 p.m. New York time on August 1, 2022. The “free writing prospectus” as defined in Rule 405 under the Securities Act for which each party hereto has received consent to use in accordance with Section 7 of the Underwriting Agreement is listed in Schedule III hereto and is attached as Exhibit A hereto.
Singapore Securities and Futures Act Product Classification – In connection with Section 309B of the Securities and Futures Xxx 0000 of Singapore (the “SFA”) and the Securities and Futures (Capital Markets Products) Regulations 2018 of Singapore (the “CMP Regulations 2018”), the Company has determined, and hereby notifies all relevant persons (as defined in Section 309A(1) of the SFA), that the Securities are “prescribed capital markets products” (as defined in the CMP Regulations 2018) and Excluded Investment Products (as defined in MAS Notice SFA 04-N12: Notice on the Sale of Investment Products and MAS Notice FAA-N16L Notice on Recommendations on Investment Products).
If the foregoing is in accordance with your understanding, please sign and return to us the counterpart hereof, and upon acceptance hereof by you, on behalf of each of the Underwriters, this letter and such acceptance hereof, including the provisions of the Underwriting Agreement incorporated herein by reference, shall constitute a binding agreement between each of the Underwriters on the one hand and the Company on the other.
[Signature Page Follows]
| Very truly yours, |
| BARCLAYS PLC |
| /s/ Xxxxxx Xxxxx |
| Name: Xxxxxx Xxxxx |
| Title: Director |
| Accepted as of the date hereof at New York, New York |
| On behalf of itself and each of the other Underwriters |
| BARCLAYS CAPITAL INC. |
| /s/ Xxxxxx Xxxxx |
| Name: Xxxxxx Xxxxx |
| Title: Director |
[Signature Page to Contingent Convertible Pricing Agreement]
SCHEDULE I
| Underwriter |
Principal Amount of the Designated Securities |
|||
| Barclays Capital Inc. |
$ | 1,546,250,000 | ||
| BNP Paribas Securities Corp. |
$ | 25,000,000 | ||
| Citigroup Global Markets Inc. |
$ | 25,000,000 | ||
| Commerz Markets LLC |
$ | 25,000,000 | ||
| ING Financial Markets LLC |
$ | 25,000,000 | ||
| X.X. Xxxxxx Securities LLC |
$ | 25,000,000 | ||
| Natixis Securities Americas LLC |
$ | 25,000,000 | ||
| Santander Investment Securities Inc. |
$ | 25,000,000 | ||
| SMBC Nikko Securities America, Inc. |
$ | 25,000,000 | ||
| TD Securities (USA) LLC |
$ | 25,000,000 | ||
| UBS Securities LLC |
$ | 25,000,000 | ||
| UniCredit Capital Markets LLC |
$ | 25,000,000 | ||
| BBVA Securities Inc. |
$ | 9,375,000 | ||
| BMO Capital Markets Corp. |
$ | 9,375,000 | ||
| CIBC World Markets Corp. |
$ | 9,375,000 | ||
| Danske Markets Inc. |
$ | 9,375,000 | ||
| Deutsche Bank Securities Inc. |
$ | 9,375,000 | ||
| Lloyds Securities Inc. |
$ | 9,375,000 | ||
| Mizuho Securities USA LLC |
$ | 9,375,000 | ||
| nabSecurities, LLC |
$ | 9,375,000 | ||
| Nordea Bank ABP |
$ | 9,375,000 | ||
| SG Americas Securities, LLC |
$ | 9,375,000 | ||
| Academy Securities, Inc. |
$ | 5,000,000 | ||
| AmeriVet Securities, Inc. |
$ | 5,000,000 | ||
| Xxxxxxxx Capital, LLC |
$ | 5,000,000 | ||
| Xxxxxxxx Van, LLC |
$ | 5,000,000 | ||
| Citizens Capital Markets, Inc. |
$ | 5,000,000 | ||
| X.X. Xxxx & Associates, Inc. |
$ | 5,000,000 | ||
| Great Pacific Securities |
$ | 5,000,000 | ||
| Loop Capital Markets LLC |
$ | 5,000,000 | ||
| Xxxxxxxx Financial Group, Inc. |
$ | 5,000,000 | ||
| PNC Capital Markets LLC |
$ | 5,000,000 | ||
| QNB Capital LLC |
$ | 5,000,000 | ||
| Xxxxxxx and Xxxx Investments Inc |
$ | 5,000,000 | ||
| X. Xxxxxxx & Co., LLC |
$ | 5,000,000 | ||
| Xxxxxx X. Xxxxxxx & Company, Inc. |
$ | 5,000,000 | ||
| Xxxxx Brothers & Co |
$ | 5,000,000 | ||
| Telsey Advisory Group LLC |
$ | 5,000,000 | ||
| U.S. Bancorp Investments, Inc. |
$ | 5,000,000 | ||
| Total |
$ | 2,000,000,000 | ||
SCHEDULE II
Title of Designated Securities:
$2,000,000,000 8.000% Fixed Rate Resetting Perpetual Subordinated Contingent Convertible Securities.
Price to Public:
100.000% of principal amount.
Subscription Price by Underwriters:
1.000% of the aggregate principal amount with respect to the Designated Securities.
Form of Designated Securities:
The Designated Securities will be represented by one or more global securities registered in the name of Cede & Co., as nominee of DTC issued pursuant to the Contingent Capital Securities Indenture dated August 14, 2018 (as heretofore amended and supplemented), between Barclays PLC, The Bank of New York Xxxxxx XX/NV, Luxembourg Branch, as contingent capital registrar (the “Registrar”) and The Bank of New York Mellon, London branch, as trustee (the “Trustee”), as supplemented by the Seventh Supplemental Indenture to be dated on or about August 8, 2022, between Barclays PLC, the Registrar and the Trustee.
Securities Exchange, if any:
The International Securities Market of the London Stock Exchange.
Interest Rate:
From (and including) the date of issuance to (but excluding) September 15, 2029 the interest rate on the Designated Securities will be 8.000% per annum. From (and including) each Reset Date (as defined below) to (but excluding) the next following Reset Date, the applicable per annum interest rate will be equal to the sum, as determined by the Calculation Agent, of the applicable U.S. Treasury Rate (as defined below, such term subject to the provisions described under “Description of Fixed Rate Resetting Perpetual Subordinated Contingent Convertible Securities—Determination of Subsequent Interest Rate” in the Preliminary Prospectus Supplement (as defined below)) on the relevant Reset Determination Date (as defined below) and 5.431% (the “Subsequent Interest Rate”).
U.S. Treasury Rate:
The U.S. Treasury Rate shall be the rate described under “Description of Fixed Rate Resetting Perpetual Subordinated Contingent Convertible Securities—Determination of Subsequent Interest Rate—U.S. Treasury Rate and fallbacks” in the Preliminary Prospectus Supplement.
Determination of Subsequent Interest Rate:
If the U.S. Treasury Rate is not available on the Reset Determination Date (as defined in the Preliminary Prospectus Supplement) for whatever reason, the relevant Subsequent Interest Rate shall instead be determined as set out under “Description of Fixed Rate Resetting Perpetual Subordinated Contingent Convertible Securities—Determination of Subsequent Interest Rate—U.S. Treasury Rate and Fallbacks” in the Preliminary Prospectus Supplement (as supplemented by the final term sheet dated August 1, 2022).
Interest Payment Dates:
March 15, June 15, September 15 and December 15 of each year (each an “Interest Payment Date”), commencing on December 15, 2022. A payment made on that first Interest Payment Date, if any, would be in respect of the period from (and including) August 8, 2022, to (but excluding) December 15, 2022 (and thus a long first interest period).
Business Day:
The term “Business Day” means any weekday, other than one on which banking institutions are authorized or obligated by law, regulation or executive order to close in London, United Kingdom, or in New York City, New York.
Reset Date:
September 15, 2029, and each fifth anniversary date thereafter (each a “Reset Date”).
Reset Determination Date:
The second Business Day immediately preceding each Reset Date (each a “Reset Determination Date”).
Regular Record Dates:
The regular record dates for the Designated Securities will be the close of business on the Business Day immediately preceding each Interest Payment Date (or, if the Designated Securities are held in definitive form, the close of business on the 15th Business Day preceding each Interest Payment Date).
Sinking Fund Provisions:
No sinking fund provisions.
Redemption Provisions for Designated Securities:
Subject to certain conditions, the Designated Securities are redeemable, in whole but not in part, at the option of the Company, (i) on any day falling in the period commencing on (and including) March 15, 2029 and ending on (and including) the first Reset Date or on any subsequent Reset Date, (ii) in the event of a change in certain U.K. regulatory capital requirements and (iii) upon the occurrence of certain tax events, in each case as specified in the Preliminary Prospectus Supplement (as supplemented by the final term sheet dated August 1, 2022) relating to the Designated Securities.
Time of Delivery:
August 8, 2022 by 9.30 a.m., New York time.
Specified Funds for Payment of Subscription Price of Designated Securities:
By wire transfer to a bank account specified by the Company in same day funds.
Value Added Tax:
(a) If the Company is obliged to pay any sum to the Underwriters under this Agreement and any value added tax (“VAT”) is properly charged on such amount, the Company shall pay to the Underwriters an amount equal to such VAT on receipt of a valid VAT invoice;
(b) If the Company is obliged to pay a sum to the Underwriters under this Agreement for any fee, cost, charge or expense properly incurred under or in connection with this Agreement (the “Relevant Cost”) and no VAT is payable by the Company in respect of the Relevant Cost under paragraph (a) above, the Company shall pay to the Underwriters an amount which:
(i) if for VAT purposes the Relevant Cost is consideration for a supply of goods or services made to the Underwriters, is equal to any input VAT incurred by the Underwriters on that supply of goods and services, but only if and to the extent that the Underwriters are unable to recover such input VAT from HM Revenue & Customs (whether by repayment or credit) provided, however, that the Underwriters shall reimburse the Company for any amount paid by the Company in respect of irrecoverable input VAT pursuant to this paragraph (i) if and to the extent such input VAT is subsequently recovered from HM Revenue & Customs (whether by repayment or credit);
(ii) if for VAT purposes the Relevant Cost is a disbursement properly incurred by the Underwriters under or in connection with this Agreement as agent on behalf of the Company, is equal to any VAT paid on the Relevant Cost by the Underwriters provided, however, that the Underwriters shall use best endeavors to procure that the actual supplier of the goods or services which the Underwriters received as agent issues a valid VAT invoice to the Company.
Closing Location:
Linklaters LLP, Xxx Xxxx Xxxxxx, Xxxxxx XX0X 0XX, Xxxxxx Xxxxxxx.
Name and address of Representative:
Designated Representative: Barclays Capital Inc.
Address for Notices:
Barclays Capital Inc.
000 Xxxxxxx Xxxxxx
Xxx Xxxx, XX 00000
Attn: Syndicate Registration
Selling Restrictions:
United Kingdom:
Each Underwriter represents, warrants and agrees with the Company that, in connection with the distribution of the Designated Securities, directly or indirectly, it (i) has only communicated or caused to be communicated, and will only communicate or cause to be communicated, an invitation or inducement to engage in investment activity (within the meaning of Section 21 of the Financial Services and Markets Xxx 0000, as amended (the “FSMA”)) received by it in connection with the issue or sale of any Designated Securities in circumstances in which Section 21(1) of the FSMA does not apply to the Company; and (ii) has complied and will comply with all applicable provisions of the FSMA with respect to anything done by it in relation to the Designated Securities in, from or otherwise involving the United Kingdom.
Prohibition of Sales to United Kingdom Retail Investors:
Each Underwriter represents, warrants and agrees with the Company that it has not offered, sold or otherwise made available and will not offer, sell or otherwise make available any Designated Securities to any retail investor in the United Kingdom. For the purposes of this provision, the expression “retail investor” means a person who is one (or more) of the following:
| (i) | a retail client, as defined in point (8) of Article 2 of Regulation (EU) No 2017/565 as it forms part of domestic law of the United Kingdom by virtue of the U.K. European Union (Withdrawal Act) 2018 (“Withdrawal Act”); or |
| (ii) | a customer within the meaning of the provisions of the FSMA and any rules or regulations made under the FSMA to implement Directive (EU) 2016/97, where that customer would not qualify as a professional client, as defined in point (8) of Article 2(1) of Regulation (EU) No 600/2014 as it forms part of domestic law of the United Kingdom by virtue of the Withdrawal Act. |
Prohibition of Sales to European Economic Area Retail Investors:
Each Underwriter represents, warrants and agrees with the Company that it has not offered, sold or otherwise made available and will not offer, sell or otherwise make available any Designated Securities to any retail investor in the European Economic Area. For the purposes of this provision, the expression “retail investor” means a person who is one (or more) of the following:
| (i) | a retail client as defined in point (11) of Article 4(1) of Directive 2014/65/EU (as amended, “MiFID II”); or |
| (ii) | a customer within the meaning of the Directive (EU) 2016/97 (as amended), where that customer would not qualify as a professional client as defined in point (10) of Article 4(1) of MiFID II. |
Canada:
Each Underwriter represents, warrants and agrees with the Company, with respect to sales of the Designated Securities in Canada, that, directly or indirectly, it shall sell the Designated Securities only to purchasers purchasing as principal that are both “accredited investors” as defined in National Instrument 45-106 Prospectus Exemptions or section 73.3 of the Securities Act (Ontario) and “permitted clients” as defined in National Instrument 31-103 Registration Requirements, Exemptions and Ongoing Registrant Obligations.
Hong Kong:
Each Underwriter represents, warrants and agrees that:
| (i) | it has not offered or sold and will not offer or sell in Hong Kong, by means of any document, any Designated Securities other than (a) to “professional investors” as defined in the Securities and Futures Ordinance (Cap. 571) of Hong Kong (the “SFO”) and any rules made under the SFO; or (b) in other circumstances which do not result in the document being a “prospectus” as defined in the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Cap. 32) of Hong Kong (the “C(WUMP)O”) or which do not constitute an offer to the public within the meaning of the C(WUMP)O; and |
| (ii) | it has not issued or had in its possession for the purposes of issue, and will not issue or have in its possession for the purposes of issue, whether in Hong Kong or elsewhere, any advertisement, invitation or document relating to the Designated Securities, which is directed at, or the contents of which are likely to be accessed or read by, the public of Hong Kong (except if permitted to do so under the securities laws of Hong Kong) other than with respect to Designated Securities which are or are intended to be disposed of only to persons outside Hong Kong or only to “professional investors” as defined in the SFO and any rules made under the SFO. |
Singapore:
Each Underwriter acknowledges that the prospectus supplement, incorporating the Base Prospectus, has not been registered as a prospectus with the Monetary Authority of Singapore. Accordingly, each Underwriter represents, warrants and agrees that it has not offered or sold any Designated Securities or caused the Designated Securities to be made the subject of an invitation for subscription or purchase and will not offer or sell any Designated Securities or cause the Designated Securities to be made the subject of an invitation for subscription or purchase, and has not circulated or distributed, nor will it circulate or distribute, the prospectus supplement and the Base Prospectus or any other document or material in connection with the offer or sale, or invitation for subscription or purchase, of the Designated Securities, whether directly or indirectly, to any person in Singapore other than (i) to an institutional investor (as defined in Section 4A of the SFA) pursuant to Section 274 of the SFA, (ii) to a relevant person (as defined in Section 275(2) of the SFA) pursuant to Section 275(1) of the SFA, or any person pursuant to Section 275(1A) of the SFA, and in accordance with the conditions specified in Section 275 of the SFA, or (iii) otherwise pursuant to, and in accordance with the conditions of, any other applicable provision of the SFA.
Where the Designated Securities are subscribed or purchased under Section 275 of the SFA by a relevant person which is:
| (a) | a corporation (which is not an accredited investor (as defined in Section 4A of the SFA)) the sole business of which is to hold investments and the entire share capital of which is owned by one or more individuals, each of whom is an accredited investor; or |
| (b) | a trust (where the trustee is not an accredited investor) whose sole purpose is to hold investments and each beneficiary of the trust is an individual who is an accredited investor, securities or securities-based derivatives contracts (each term as defined in Section 2(1) of the SFA) of that corporation or the beneficiaries’ rights and interest (howsoever described) in that trust shall not be transferred within six months after that corporation or that trust has acquired the Designated Securities pursuant to an offer made under Section 275 of the SFA except: |
| (1) | to an institutional investor or to a relevant person or to any person arising from an offer referred to in Section 275(1A) or Section 276(4)(c)(ii) of the SFA; |
| (2) | where no consideration is or will be given for the transfer; |
| (3) | where the transfer is by operation of law; |
| (4) | as specified in Section 276(7) of the SFA; or |
| (5) | as specified in Regulation 37A of the Securities and Futures (Offers of Investments) (Securities and Securities-based Derivatives Contracts) Regulations 2018 of Singapore. |
Japan:
The Designated Securities have not been and will not be registered under the Financial Instruments and Exchange Act of Japan (Act No. 25 of 1948, as amended, the “FIEA”) and accordingly, each Underwriter undertakes that it will not offer or sell any Designated Securities directly or indirectly, in Japan or to, or for the benefit of, any resident of Japan or to others for re-offering or resale, directly or indirectly, in Japan or to any resident of Japan except pursuant to an exemption from the registration requirements of, and otherwise in compliance with the FIEA and other relevant laws and regulations of Japan. As used in this paragraph, “resident of Japan” means any person resident in Japan, including any corporation or other entity organized under the laws of Japan.
Australia:
No “prospectus” or other “disclosure document” (as defined in the Corporations Xxx 0000 of Australia (the “Corporations Act”)) in relation to the Designated Securities has been, or will be, lodged with, or registered by, the Australian Securities and Investments Commission (“ASIC”) or any other regulatory authority in Australia. Each Underwriter represents warrants and agrees that it:
| (a) | has not (directly or indirectly) offered or invited applications, and will not offer or invite applications, for the issue, sale or purchase of, any Designated Securities in, to or from Australia (including an offer or invitation which is received by a person in Australia); and |
| (b) | has not distributed or published, and will not distribute or publish, the prospectus supplement, the accompanying prospectus or any other offering material or advertisement relating to the Designated Securities in Australia, |
unless:
| (i) | the aggregate consideration payable by each offeree or invitee is at least AUD500,000 (or its equivalent in an alternative currency and, in either case, disregarding moneys lent by the offeror or its associates) or the offer or invitation otherwise does not require disclosure to investors in accordance with Part 6D.2 or Part 7.9 of the Corporations Act and complies with the terms of any consent granted under the Banking Act of 1959 of Australia; |
| (ii) | the offer or invitation is not made to a person who is a “retail client” within the meaning of section 761G of the Corporations Act; |
| (iii) | such action complies with all applicable laws, regulations and directives in Australia (including without limitation, the licensing requirements set out in Chapter 7 of the Australian Corporations Act); and |
| (iv) | such action does not require any document to be lodged with ASIC or any other regulatory authority in Australia. |
The prospectus supplement and the accompanying prospectus are not, under any circumstances to be construed as, an advertisement or public offering of any Designated Securities in Australia.
In addition, each underwriter has represented and agreed that all offers, invitations and transfers by such underwriter which occur within Australia are to be in parcels of not less than AUD500,000 in aggregate principal amount. Such restriction does not apply to transfers which occur outside of Australia.
By applying for Designated Securities under the prospectus supplement and the Base Prospectus, each person to whom Designated Securities are issued (an “Investor”):
| (a) | will be deemed by the Company and each of the Underwriters to have acknowledged that if any Investor on-sells Designated Securities within 12 months from their issue, the Investor will be required to lodge a prospectus or other disclosure document (as defined in the Corporations Act) with ASIC unless either: |
| (i) | that sale is to an investor within one of the categories set out in sections 708(8) or 708(11) of the Corporations Act to whom it is lawful to offer Designated Securities in Australia without a prospectus or other disclosure document lodged with ASIC; or |
| (ii) | the sale offer is received outside Australia; and |
will be deemed by the Company and each of the Underwriters to have undertaken not to sell those Designated Securities in any circumstances other than those described in paragraphs (a)(i) and (a)(ii) above for 12 months after the date of issue of such Designated Securities.
Taiwan:
Each Underwriter represents, warrants and agrees with the Company that it has not offered, sold or otherwise made available and will not offer, sell or otherwise make available any Designated Securities within Taiwan, the Republic of China (“Taiwan”) through a public offering or in circumstances which constitute an offer within the meaning of the Taiwan Securities and Exchange Act or relevant laws and regulations that requires a registration, filing or approval of the Financial Supervisory Commission of Taiwan and/or other regulatory authority of the Taiwan. Each Underwriter further represents, warrants and agrees with the Company that no person or entity in Taiwan is authorized to offer, sell or otherwise make available any Designated Securities or the provision of information relating to the prospectus supplement and the Base Prospectus.
Other Terms and Conditions:
As set forth in the prospectus supplement dated August 1, 2022 relating to the Designated Securities (the “Preliminary Prospectus Supplement”), incorporating the Prospectus dated March 1, 2021 relating to the Designated Securities (the “Base Prospectus”).
SCHEDULE III
Issuer Free Writing Prospectus:
Final Term Sheet, dated August 1, 2022 attached hereto as Exhibit A.
EXHIBIT A
Free Writing Prospectus
Filed pursuant to Rule 433
Registration Statement No. 333-253693
$2,000,000,000 8.000% Fixed Rate Resetting Perpetual Subordinated Contingent
Convertible Securities
Pricing Term Sheet
| Issuer | Barclays PLC (the “Issuer”). | |
| Securities | $2,000,000,000 8.000% Fixed Rate Resetting Perpetual Subordinated Contingent Convertible Securities (the “Securities”). | |
| Expected Issue Ratings1 | Ba2 (Moody’s) / B+ (S&P) / BBB- (Fitch) | |
| Status | Perpetual Subordinated Contingent Convertible Securities. | |
| Legal Format | SEC registered. | |
| Principal Amount | $2,000,000,000 | |
| Trade Date | August 1, 2022 | |
| Settlement Date | August 8, 2022 (T+5) (the “Issue Date”). | |
| Maturity Date | Perpetual, with no fixed maturity or fixed redemption date. | |
| Optional Call Dates | On any day falling in the period commencing on (and including) March 15, 2029 and ending on (and including) the first Reset Date (as defined below) or on any subsequent Reset Date. | |
| Preliminary Prospectus Supplement | Preliminary prospectus supplement dated August 1, 2022 (the “Preliminary Prospectus Supplement”) incorporating the Prospectus dated March 1, 2021 relating to the Securities (the “Base Prospectus”). If there is any discrepancy or contradiction between this Pricing Term Sheet and the Preliminary Prospectus Supplement, this Pricing Term Sheet shall prevail. | |
| U.K. Bail-in Power Acknowledgment | Yes. See section entitled “Description of Contingent Capital Securities—Agreement with Respect to the Exercise of U.K. Bail-in Power” in the Base Prospectus. | |
| Initial Interest Period | ||
| Initial Fixed Rate | 8.000% per annum, from and including August 8, 2022 to, but excluding, September 15, 2029. | |
| Initial Interest Payment Dates | Quarterly in arrear on March 15, June 15, September 15 and December 15 of each year up to and including September 15, 2029, commencing on December 15, 2022 (long first interest period). | |
| U.S. Treasury | UST 2 5/8% due July 31, 2029 | |
| U.S. Treasury Rate / Price | 2.647% / 99-27+ | |
| 1 | Note: A securities rating is not a recommendation to buy, sell or hold securities and may be subject to revision or withdrawal at any time. |
| Interest Periods Following Any Reset Date | ||
| Interest Rate Following Any Reset Date | The applicable U.S. Treasury Rate (such term subject to the provisions described under “Description of Fixed Rate Resetting Perpetual Subordinated Contingent Convertible Securities—Determination of Subsequent Interest Rate” in the Preliminary Prospectus Supplement) on the relevant Reset Determination Date (as defined below) plus the Margin (as defined below) (the “Subsequent Interest Rate”), from and including the relevant Reset Date to (but excluding) the next following Reset Date. | |
| Reset Date | September 15, 2029, and each fifth anniversary thereafter (each a “Reset Date”). | |
| Interest Payment Dates Following Any Reset Date | Quarterly in arrear on March 15, June 15, September 15 and December 15 of each year commencing on December 15, 2029. | |
| Spread to U.S. Treasury Rate | 543.1bps (the “Margin”). | |
| Reset Determination Date | The second Business Day immediately preceding each Reset Date (each a “Reset Determination Date”). | |
| U.S. Treasury Rate and fallbacks | “U.S. Treasury Rate” means, with respect to any Reset Period for which such rate applies, the rate per annum equal to: (1) the yield, under the heading which represents the average for the week immediately prior to the applicable Reset Determination Date, appearing in the most recently published statistical release designated “H.15”, or any successor publication that is published by the Board of Governors of the Federal Reserve System that establishes yields on actively traded U.S. Treasury securities adjusted to constant maturity, under the caption “Treasury constant maturities”, for the maturity of five years; or (2) if such release (or any successor release) is not published during the week immediately prior to such Reset Determination Date or does not contain such yields, the rate per annum equal to the semi-annual equivalent yield to maturity of the Comparable Treasury Issue, calculated using a price for the Comparable Treasury Issue (expressed as a percentage of its principal amount) equal to the Comparable Treasury Price for such Reset Determination Date.
The U.S. Treasury Rate shall be calculated by the Calculation Agent (as defined below).
If the U.S. Treasury Rate cannot be determined, for whatever reason, as described under (1) or (2) above, “U.S. Treasury Rate” means the rate in percentage per annum as notified by the Calculation Agent to the Issuer equal to the yield on U.S. Treasury securities having a maturity of five years as set forth in the most recently published statistical release designated “H.15” under the caption “Treasury constant maturities” (or any successor publication that is published weekly by the Board of Governors of the Federal Reserve System and that establishes yields on actively traded U.S. Treasury securities adjusted to constant maturity under the caption “Treasury constant maturities” for the maturity of five years) at 5:00 p.m. (New York City time) on the last available date preceding the Reset Determination Date on which such rate was set forth in such release (or any successor release). | |
| Certain Other Terms and Information | ||
| Business Days | “Business Day” means any weekday, other than one on which banking institutions are authorized or obligated by law, regulation or executive order to close in London, United Kingdom, or in New York City, New York. | |
| Day Count Fraction | 30/360, following, unadjusted. | |
| Interest Payments Discretionary | Interest on the Securities will be due and payable only at the sole discretion of the Issuer, as described under “Description of Fixed Rate Resetting Perpetual Subordinated Contingent Convertible Securities—Interest Cancellation—Interest Payments Discretionary” in the Preliminary Prospectus Supplement. | |
| Restriction on Interest Payments | As described in the Preliminary Prospectus Supplement, the Issuer shall not make an interest payment on the Securities on any interest payment date (and such interest payment shall therefore be deemed to have been cancelled and thus shall not be due and payable on such interest payment date) if: | |
| (1) the Issuer has an amount of Distributable Items on such interest payment date that is less than a certain level; or | ||
| (2) the Solvency Condition is not satisfied in respect of such interest payment, as further described under “Description of Fixed Rate Resetting Perpetual Subordinated Contingent Convertible Securities—Interest Cancellation—Restriction on Interest Payments” in the Preliminary Prospectus Supplement. | ||
| Agreement to Interest Cancellation | By subscribing for, purchasing or otherwise acquiring the Securities, holders of the Securities acknowledge and agree to the provisions described under “Description of Fixed Rate Resetting Perpetual Subordinated Contingent Convertible Securities—Interest Cancellation—Agreement to Interest Cancellation” in the Preliminary Prospectus Supplement. | |
| Ranking | Subordinated to the claims of Senior Creditors (as defined below), as described in further detail in the Preliminary Prospectus Supplement.
“Senior Creditors” means creditors of the Issuer (i) who are unsubordinated creditors; (ii) whose claims are, or are expressed to be, subordinated (whether only in the event of the winding-up or administration of the Issuer or otherwise) to the claims of unsubordinated creditors of the Issuer but not further or otherwise; (iii) who are creditors in respect of any secondary non-preferential debts; or (iv) whose claims are, or are expressed to be, junior to the claims of other creditors of the Issuer, whether subordinated or unsubordinated, other than those whose claims rank, or are expressed to rank, pari passu with, or junior to, the claims of the holders of the Securities. | |
| Capital Adequacy Trigger Event | A “Capital Adequacy Trigger Event” shall occur if at any time the fully loaded CET1 Ratio is less than 7.00%.
Whether a Capital Adequacy Trigger Event has occurred at any time shall be determined by the Issuer and such determination shall be binding on the trustee and holders of the Securities. | |
| Automatic Conversion Upon Capital Adequacy Trigger Event | An Automatic Conversion will occur without delay upon the occurrence of a Capital Adequacy Trigger Event. | |
| “Automatic Conversion” means the irrevocable and automatic release of all of the Issuer’s obligations under the Securities (other than the CSO Obligations, if any) in consideration of the Issuer’s issuance of the Conversion Shares at the Conversion Price to the Conversion Shares Depository (on behalf of the holders of the Securities) or to the relevant recipient, in accordance with the terms of the Securities and as described in the Preliminary Prospectus Supplement. | ||
| Conversion Price | $2.02 per Conversion Share, subject to certain anti-dilution adjustments, as described under “Description of Fixed Rate Resetting Perpetual Subordinated Contingent Convertible Securities—Anti-Dilution” in the Preliminary Prospectus Supplement and the provisions described under “Description of Fixed Rate Resetting Perpetual Subordinated Contingent Convertible Securities—Conversion Shares Offer” in the Preliminary Prospectus Supplement. On the Issue Date, the Conversion Price is equivalent to the Conversion Shares Offer Price (as defined herein) translated into U.S. dollars at an exchange rate of £1.00 = $1.23. | |
| Conversion Shares Offer | Following an Automatic Conversion, the Issuer may, in its sole and absolute discretion, elect that the Conversion Shares Depository make an offer of all or some of the Conversion Shares to all or some of the Issuer’s ordinary shareholders at such time at a cash price per Conversion Share equal to the Conversion Shares Offer Price, as further described in the Preliminary Prospectus Supplement. | |
| Conversion Shares Offer Price | £1.65 per Conversion Share (subject to certain anti-dilution adjustments, as described in the Preliminary Prospectus Supplement). | |
| Optional Redemption | The Securities are redeemable, in whole but not in part, on any day falling in the period commencing on (and including) March 15, 2029 and ending on (and including) the first Reset Date or on any subsequent Reset Date at the option of the Issuer, as described under “Description of Fixed Rate Resetting Perpetual Subordinated Contingent Convertible Securities—Redemption—Optional Redemption” in the Preliminary Prospectus Supplement. | |
| Regulatory Event Redemption | The Securities are also redeemable, in whole but not in part, at any time at the option of the Issuer in the event of a change in certain U.K. regulatory capital requirements, as described under “Description of Fixed Rate Resetting Perpetual Subordinated Contingent Convertible Securities—Redemption—Regulatory Event Redemption” in the Preliminary Prospectus Supplement. | |
| Tax Redemption | The Securities are also redeemable, in whole but not in part, at any time at the option of the Issuer upon the occurrence of certain tax events, as described under “Description of Fixed Rate Resetting Perpetual Subordinated Contingent Convertible Securities—Redemption—Tax Redemption” in the Preliminary Prospectus Supplement. | |
| Denominations | $200,000 and integral multiples of $1,000 in excess thereof. | |
| ISIN / CUSIP / FISN / CFI Code | US06738EBX22 / 06738E BX2 / BARCLAYS PLC/NT CONV PERP SUB / DCFUQR | |
| Legal Entity Identifier (“LEI”) Code | 213800LBQA1Y9L22JB70 | |
| Reoffer Yield | 8.078% (Semi Annual). | |
| Issue Price | 100.000%. | |
| Estimated Underwriter Compensation | 1.000% of the principal amount of the Securities. | |
| Estimated Net Proceeds | $1,980,000,000 | |
| Sole Structuring Adviser and Sole Bookrunner | Barclays Capital Inc. | |
| Joint Lead Managers (no books) | BNP Paribas Securities Corp., Citigroup Global Markets Inc., Commerz Markets LLC, ING Financial Markets LLC, X.X. Xxxxxx Securities LLC, Natixis Securities Americas LLC, Santander Investment Securities Inc., SMBC Nikko Securities America, Inc., TD Securities (USA) LLC, UBS Securities LLC, UniCredit Capital Markets LLC | |
| Senior Co-Managers | BBVA Securities Inc., BMO Capital Markets Corp., CIBC World Markets Corp., Danske Markets Inc., Deutsche Bank Securities Inc., Lloyds Securities Inc., Mizuho Securities USA LLC, nabSecurities, LLC, Nordea Bank ABP, SG Americas Securities, LLC | |
| Co-Managers | Academy Securities, Inc., AmeriVet Securities, Inc., Xxxxxxxx Capital, LLC, Xxxxxxxx Van, LLC, Citizens Capital Markets, Inc., X.X. Xxxx & Associates, Inc., Great Pacific Securities, Loop Capital Markets LLC, Xxxxxxxx Financial Group, Inc., PNC Capital Markets LLC, QNB Capital LLC, Xxxxxxx and Xxxx Investments Inc, X. Xxxxxxx & Co., LLC, Xxxxxx X. Xxxxxxx & Company, Inc., Xxxxx Brothers & Co, Telsey Advisory Group LLC, U.S. Bancorp Investments, Inc. | |
| Documentation | To be documented under the Issuer’s shelf registration statement on Form F-3 (No. 333-253693) and to be issued pursuant to the Contingent Capital Securities Indenture dated August 14, 2018 (as heretofore amended and supplemented), between the Issuer, The Bank of New York Xxxxxx XX/NV, Luxembourg Branch, as contingent capital registrar (the “Registrar”) and The Bank of New York Mellon, London Branch, as trustee (the “Trustee”), as supplemented by the Seventh Supplemental Indenture, to be entered into on or about the Issue Date, between the Issuer, the Registrar and the Trustee. | |
| Risk Factors | An investment in the Securities involves risks. See “Risk Factors” section beginning on page S-26 of the Preliminary Prospectus Supplement. | |
| Settlement | The Depository Trust Company. | |
| Listing | International Securities Market of the London Stock Exchange. | |
| Calculation Agent | The Bank of New York Mellon, London Branch, or its successor appointed by the Issuer. | |
| Governing Law | New York law, except for subordination provisions and waiver of set-off provisions which will be governed by English law. | |
| Definitions | Unless otherwise defined herein, all capitalized terms have the meaning set forth in the Preliminary Prospectus Supplement. | |
The Issuer has filed a registration statement (including the Base Prospectus and the Preliminary Prospectus Supplement) with the U.S. Securities and Exchange Commission (the “SEC”) for this offering. Before you invest, you should read each of the Base Prospectus, the Preliminary Prospectus Supplement for this offering in that registration
statement, and the other documents the Issuer has filed with the SEC for more complete information about the Issuer and this offering. You may get these documents for free by searching the SEC online database (XXXXX) at xxx.xxx.xxx. Alternatively, you may obtain a copy of the Base Prospectus and the Preliminary Prospectus Supplement from Barclays Capital Inc. by calling 0-000-000-0000.
U.K. FCA CoCo restriction. No PRIIPs or U.K. PRIIPs key information document (KID) has been prepared as not available to retail in EEA or in the United Kingdom. No sales to retail clients (as defined in COBS 3.4) in the U.K.
It is expected that delivery of the Securities will be made for value on or about August 8, 2022, which will be the fifth (5th) business day in the United States following the date of pricing of the Securities. Under Rule 15c6-1 under the Securities Exchange Act of 1934, purchases or sales of Securities in the secondary market generally are required to settle within two (2) business days (T+2), unless the parties to any such transaction expressly agree otherwise. Accordingly, purchasers of the Securities who wish to trade the Securities on the date of this prospectus supplement or the next two (2) succeeding business days, will be required, because the Securities initially will settle within five (5) business days (T+5) in the United States, to specify an alternate settlement cycle at the time of any such trade to prevent a failed settlement. Purchasers of the Securities who wish to trade on the date of this prospectus supplement or the next two (2) succeeding business days should consult their own legal advisers.
This communication is being distributed to, and is directed only at, persons in the United Kingdom in circumstances where section 21(1) of the Financial Services and Markets Xxx 0000, as amended, does not apply (such persons being referred to as “relevant persons”). Any person who is not a relevant person should not act or rely on this communication or any of its contents. Any investment activity (including, but not limited to, any invitation, offer or agreement to subscribe, purchase or otherwise acquire securities) to which this communication relates will only be available to, and will only be engaged with, relevant persons.
Singapore SFA Product Classification – In connection with Section 309B of the Securities and Futures Xxx 0000 of Singapore (the “SFA”) and the Securities and Futures (Capital Markets Products) Regulations 2018 of Singapore (the “CMP Regulations 2018”), the Issuer has determined, and hereby notifies all relevant persons (as defined in Section 309A(1) of the SFA), that the Securities are “prescribed capital markets products” (as defined in the CMP Regulations 2018) and Excluded Investment Products (as defined in MAS Notice SFA 04-N12: Notice on the Sale of Investment Products and MAS Notice FAA-N16L Notice on Recommendations on Investment Products).
To the extent any dealer that is not a U.S. registered broker-dealer intends to effect any offers or sales of any Securities in the United States, it will do so through one or more U.S. registered broker-dealers in accordance with the applicable U.S. securities laws and regulations.
